Impact of iron overload by transfusion on survival and leukemia transformation of myelodysplastic syndromes in a single center of China

被引:5
|
作者
Wang, Yihao [1 ]
Huang, Lei [1 ]
Hua, Yanni [1 ,2 ]
Liu, Hui [1 ]
Jiang, Huijuan [1 ]
Wang, Huaquan [1 ]
Zhang, Wei [1 ]
Fu, Rong [1 ]
Shao, Zonghong [1 ]
机构
[1] Tianjin Med Univ Gen Hosp, Tianjin, Peoples R China
[2] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Shanghai, Peoples R China
关键词
Iron overload; red blood cell transfusion; survival; acute myeloid leukemia; myelodysplastic syndromes; CHELATION-THERAPY; APLASTIC-ANEMIA; MDS; ERYTHROPOIESIS; HEMATOPOIESIS; MECHANISMS; IMPROVES;
D O I
10.1080/16078454.2021.1989806
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction Myelodysplastic syndromes (MDS) are a heterogeneous group of diseases which are prone to progress into acute myeloid leukemia (AML). Iron overload (IOL) caused by transfusion occurred in most MDS patients. But how IOL influences MDS progression has not been clarified yet. Methods Herein, we collected clinical data from 143 MDS patients to investigate the impacts of IOL on patients survival and AML transformation. Results We found that median survival time, 3-year survival rate, leukemia-free survival (LFS) time were significantly shorter in patients with IOL than those with non-iron overload (NIOL) (P = 0.040; P = 0.044; P = 0.037). Besides, IOL was more likely to be found in higher-risk subgroups (assessed by IPSS and WPSS) of MDS patients which also promoted 2-year AML transformation. Furthermore, the serum ferritin (SF) was significantly correlated with the overall survival (OS) of MDS patients (r = -0.311, P < 0.05). The concentrations of both intracellular iron and reactive oxygen species (ROS) in CD34(+) cells of bone marrow were higher in the IOL group than the NIOL group, respectively (P = 0.0426; P = 0.0185). Moreover, ROS level was closely correlated with the percentage of bone marrow blasts (r = 0.7200, P = 0.0370). Collectively, IOL threatened the survival of MDS patients and promoted AML transformation. Conclusion Elevated intracellular iron and ROS in CD34(+) cells of bone marrow could accelerate the abnormal proliferation of blasts.
引用
收藏
页码:874 / 880
页数:7
相关论文
共 50 条
  • [41] Clinical impact of transformation to acute myeloid leukemia in patients with higher-risk myelodysplastic syndromes
    Kota, Vamsi
    Ogbonnaya, Augustina
    Farrelly, Eileen
    Schroader, Bridgette Kanz
    Raju, Aditya
    Kristo, Fjoralba
    Dalal, Mehul
    FUTURE ONCOLOGY, 2022, 18 (36) : 4017 - 4029
  • [42] Can iron overload in patients with lower-risk myelodysplastic syndromes be reduced using erythropoiesis-stimulating agents?
    Tsang, Erica
    Leitch, Heather A.
    ANNALS OF HEMATOLOGY, 2016, 95 (01) : 73 - 78
  • [44] A prospective non-interventional study on the impact of transfusion burden and related iron toxicity on outcome in myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplantation
    Cremers, Eline M. P.
    de Witte, Theo
    de Wreede, Liesbeth
    Eikema, Diderik-Jan
    Koster, Linda
    van Biezen, Anja
    Finke, Jurgen
    Socie, Gerard
    Beelen, Dietrich
    Maertens, Johan
    Nagler, Arnon
    Kobbe, Guido
    Ziagkos, Dimitris
    Itala-Remes, Maija
    Gedde-Dahl, Tobias
    Sierra, Jorge
    Niederwieser, Dietger
    Ljungman, Per
    Beguin, Yves
    Ozkurt, Zubeyde Nur
    Anagnostopoulos, Achilles
    Jindra, Pavel
    Robin, Marie
    Kroeger, Nicolaus
    LEUKEMIA & LYMPHOMA, 2019, 60 (10) : 2404 - 2414
  • [45] Ironing out the details of iron overload in myelofibrosis: Lessons from myelodysplastic syndromes
    Carreau, Nicole
    Tremblay, Douglas
    Savona, Michael
    Kremyanskaya, Marina
    Mascarenhas, John
    BLOOD REVIEWS, 2016, 30 (05) : 349 - 356
  • [46] Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes
    Jabbour, Elias
    Kantarjian, Hagop M.
    Koller, Charles
    Taher, Ali
    CANCER, 2008, 112 (05) : 1089 - 1095
  • [47] The Clinical Significance of Iron Overload and Iron Metabolism in Myelodysplastic Syndrome and Acute Myeloid Leukemia
    Weber, Sarah
    Parmon, Anastasia
    Kurrle, Nina
    Schnuetgen, Frank
    Serve, Hubert
    FRONTIERS IN IMMUNOLOGY, 2021, 11
  • [48] Red Bood Cell Transfusion Therapy and Iron Chelation in Patients With Myelodysplastic Syndromes
    Malcovati, Luca
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S305 - S311
  • [49] When is iron overload deleterious, and when and how should iron chelation therapy be administered in myelodysplastic syndromes?
    Steensma, David P.
    Gattermann, Norbert
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2013, 26 (04) : 431 - 444
  • [50] Impact of medication adherence on the effectiveness of deferasirox for the treatment of transfusional iron overload in myelodysplastic syndrome
    Escudero-Vilaplana, V.
    Garcia-Gonzalez, X.
    Osorio-Prendes, S.
    Romero-Jimenez, R. M.
    Sanjurjo-Saez, M.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2016, 41 (01) : 59 - 63